Understanding Voting Rights and Share Capital
Voting rights play a crucial role in corporate governance, allowing shareholders to influence decisions that impact the company's future. At Nanobiotix, an innovative biotechnology firm, these rights and the dynamics of share capital are integral to its operational framework. Understanding these concepts can aid stakeholders in making informed decisions about their investments.
Overview of Nanobiotix
Nanobiotix, incorporated in 2003 and headquartered in Paris, is at the forefront of biotechnology. The company's goal is to transform cancer treatments through ground-breaking therapies based on nanotechnology. With a commitment to pushing the boundaries of medical innovation, Nanobiotix aims to offer better treatment options for patients worldwide.
The Role of Shares in Corporate Structure
Shares represent ownership in a company, and their allocation determines the voting power each shareholder holds. As of the latest update, Nanobiotix has approximately 47,426,851 shares outstanding, with a theoretical voting rights total of 49,193,374. This structure illustrates the delicate balance between share ownership and the influence shareholders have over company decisions.
Types of Voting Rights
A key aspect of understanding shares is the distinction between theoretical and exercisable voting rights. Theoretical rights include shares that are entitled to vote, while exercisable rights exclude those shares that have had their voting rights suspended. For Nanobiotix, the practical voting rights stand at 49,171,256, which reflects the real influence shareholders can exert during meetings.
Shareholder Engagement and Communication
Keeping shareholders informed is essential for a transparent and accountable corporate environment. Nanobiotix places great emphasis on shareholder communication and actively engages with its investors through its communications and investor relations departments. This is vital not only for transparency but also for fostering a sense of community among its shareholders.
Contact Information for Stakeholders
For those interested in more details about their investments or seeking clarification on corporate governance matters, Nanobiotix provides accessible contact points. The Communications Department, led by Brandon Owens, serves as a primary resource for inquiries, alongside other departments focused on investor relations.
Commitment to Innovation
Nanobiotix is dedicated to redefining treatment methodologies with its unique nanotechnology platforms. The company holds over 25 patent families which cater to diverse applications, including oncology and the central nervous system. This innovation is supported by a robust foundation of scientific research aimed at enhancing therapeutic effectiveness.
Future Directions
As the company continues to evolve, it remains committed to exploring new avenues of research and development. This steadfast focus on innovation might provide shareholders with enhanced value and positions Nanobiotix as a leader in biotechnology, particularly in the fields of targeted cancer therapies.
Frequently Asked Questions
1. What are voting rights in a company?
Voting rights allow shareholders to participate in corporate governance by voting on critical issues such as election of board members and approval of major transactions.
2. How are shares in Nanobiotix structured?
Nanobiotix has a structure of shares that include both theoretical and exercisable voting rights, providing a mechanism for shareholder participation.
3. Who can shareholders contact for inquiries?
Shareholders can reach out to the Communications Department at Nanobiotix, which is headed by Brandon Owens for any inquiries regarding their investments.
4. What focus areas does Nanobiotix specialize in?
Nanobiotix specializes in oncology, bioavailability, and disorders of the central nervous system, utilizing innovative nanotechnology platforms for its solutions.
5. When was Nanobiotix established?
Nanobiotix was founded in 2003 and has been publicly traded since then, committing to continuous breakthroughs in biotechnology.
